TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Mar 2025

Income Metrics

Revenue 1.3M
Gross Profit 241.0K 17.97%
Operating Income -22.6M -1,685.01%
Net Income -54.2M -4,038.26%
EPS (Diluted) $-0.18

Balance Sheet Metrics

Total Assets 128.8M
Total Liabilities 142.8M
Shareholders Equity -14.1M

Cash Flow Metrics

Operating Cash Flow -49.4M
Free Cash Flow -16.9M

Revenue & Profitability Trend

Precigen Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i3.9M6.2M26.9M14.3M103.2M
Cost of Goods Sold i4.3M6.1M6.3M5.7M55.5M
Gross Profit i-342.0K106.0K20.6M8.5M47.7M
Gross Margin % i-8.7%1.7%76.4%59.7%46.2%
Operating Expenses
Research & Development i53.1M48.6M47.2M47.9M41.6M
Selling, General & Administrative i41.3M40.4M48.0M52.0M91.7M
Other Operating Expenses i-----
Total Operating Expenses i94.4M89.0M95.2M99.9M133.3M
Operating Income i-94.7M-88.9M-74.6M-91.4M-85.7M
Operating Margin % i-2,412.9%-1,428.5%-277.3%-640.7%-83.0%
Non-Operating Items
Interest Income i1.4M3.2M133.0K171.0K2.5M
Interest Expense i6.0K468.0K6.8M18.8M18.4M
Other Non-Operating Income-34.7M-10.2M1.3M-978.0K-2.2M
Pre-tax Income i-128.0M-96.4M-80.0M-111.0M-103.9M
Income Tax i-1.8M-458.0K-189.0K-160.0K-82.0K
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.0%
Net Income i-126.2M-95.9M28.3M-92.2M-170.5M
Net Margin % i-3,216.2%-1,540.6%105.2%-646.0%-165.3%
Key Metrics
EBITDA i-83.2M-78.4M-61.3M-77.9M-67.0M
EPS (Basic) i$-0.47$-0.39$0.14$-0.47$-1.02
EPS (Diluted) i$-0.47$-0.39$0.14$-0.47$-1.02
Basic Shares Outstanding i267727426244536221200360821197759900167065539
Diluted Shares Outstanding i267727426244536221200360821197759900167065539

Income Statement Trend

Precigen Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i29.5M7.6M4.9M36.4M51.8M
Short-term Investments i68.4M55.3M51.1M72.2M48.3M
Accounts Receivable i926.0K902.0K978.0K1.3M16.5M
Inventory i--287.0K326.0K11.4M
Other Current Assets3.3M4.3M5.1M5.5M7.2M
Total Current Assets i102.4M68.8M118.2M156.6M148.9M
Non-Current Assets
Property, Plant & Equipment i21.8M25.7M26.1M26.8M40.5M
Goodwill i42.7M93.9M118.3M127.4M174.1M
Intangible Assets i4.5M40.7M44.5M52.3M65.4M
Long-term Investments-----
Other Non-Current Assets459.0K846.0K1.1M46.3M2.5M
Total Non-Current Assets i42.9M82.3M97.8M203.2M165.6M
Total Assets i145.3M151.0M216.0M359.9M314.6M
Liabilities
Current Liabilities
Accounts Payable i3.5M1.7M4.1M3.1M4.6M
Short-term Debt i956.0K1.2M44.4M1.4M3.0M
Current Portion of Long-term Debt-----
Other Current Liabilities---12.9M14.0M
Total Current Liabilities i21.5M23.0M78.6M34.6M42.1M
Non-Current Liabilities
Long-term Debt i4.5M5.9M7.0M188.6M179.3M
Deferred Tax Liabilities i01.8M2.3M2.5M2.9M
Other Non-Current Liabilities---50.0K100.0K
Total Non-Current Liabilities i85.2M9.6M11.1M217.9M205.3M
Total Liabilities i106.8M32.5M89.7M252.5M247.4M
Equity
Common Stock i00000
Retained Earnings i-2.1B-2.0B-1.9B-1.9B-1.8B
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i38.5M118.5M126.3M107.3M67.2M
Key Metrics
Total Debt i5.5M7.1M51.4M190.1M182.3M
Working Capital i80.9M45.8M39.5M122.0M106.8M

Balance Sheet Composition

Precigen Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-126.2M-95.9M28.3M-92.2M-170.5M
Depreciation & Amortization i4.5M6.7M10.8M13.8M17.5M
Stock-Based Compensation i9.5M9.9M10.2M13.9M18.4M
Working Capital Changes i5.4M15.5M-34.5M-3.2M-17.1M
Operating Cash Flow i-109.7M-77.4M-65.3M-61.3M-129.3M
Investing Activities
Capital Expenditures i-8.6M-1.5M-4.9M-7.2M-7.5M
Acquisitions i---00
Investment Purchases i-187.2M-185.0M0-174.2M-171.4M
Investment Sales i175.0M183.4M68.4M100.2M133.0M
Investing Cash Flow i-20.7M-3.1M64.1M-74.5M-36.5M
Financing Activities
Share Repurchases i-----
Dividends Paid i-----
Debt Issuance i---00
Debt Repayment i0-43.2M-155.3M-466.0K-12.4M
Financing Cash Flow i110.2M29.6M-155.9M120.6M20.7M
Free Cash Flow i-76.8M-68.5M-70.0M-63.0M-84.5M
Net Change in Cash i-20.2M-50.9M-157.1M-15.3M-145.1M

Cash Flow Trend

Precigen Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -8.89
Forward P/E -16.55
Price to Book -33.69
Price to Sales 249.91
PEG Ratio 0.15

Profitability Ratios

Profit Margin -8.71%
Operating Margin -3,254.32%
Return on Equity -668.03%
Return on Assets -67.44%

Financial Health

Current Ratio 2.71
Debt to Equity -0.14
Beta 1.87

Per Share Data

EPS (TTM) $-0.41
Book Value per Share $-0.12
Revenue per Share $0.02

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
pgen1.1B-8.89-33.69-668.03%-8.71%-0.14
Vertex 101.3B28.085.9022.77%31.86%8.89
Regeneron 63.6B15.122.0915.34%31.37%9.04
Sarepta Therapeutics 2.0B19.981.46-4.76%-2.34%100.51
Adaptive 2.0B-12.0411.01-57.60%-59.07%121.39
Arcutis 1.9B-13.7813.78-57.33%-35.40%79.27

Financial data is updated regularly. All figures are in the company's reporting currency.